報價延遲最少15分鐘:2025/06/04 03:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
26.52 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.25/-3.92
|
|
企業價值
278.81M
|
| 資產負債 |
|
每股賬面淨值
-0.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
20.97M
|
|
每股收益
5.94
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/04 03:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3. |